drugset / Trial / NCT07179003

A Phase 2 Study of Methylene Blue Photodynamic Therapy for Treatment of Breast Abscesses

NCT07179003

Phase 2 Not yet recruiting 50 enrolled University of Rochester
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this Phase 2 study is to evaluate the efficacy of methylene blue photodynamic therapy (MB-PDT) performed at the time of percutaneous breast abscess drainage for disinfection of breast abscesses. The study includes two arms: (1) standard of care breast abscess drainage and (2) MB-PDT plus standard of care breast abscess drainage. The primary endpoint is time to resolution of clinical symptoms. Secondary endpoints include imaging evidence of abscess resolution, abscess recurrence, need for repeated intervention, and cure rate across treatment groups. Responses will be compared between the two study arms for the per protocol population to determine the efficacy of MB-PDT relative to standard of care. The investigators hypothesize that the addition of MB-PDT to standard of care will significantly reduce the time to symptom resolution, compared to standard of care alone.

Timeline

Start
2026-04
Primary completion
2031-03
Completion
2031-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylene Blue Diagnostic / imaging agent 100 ug/ml Other
Background Intralipid Other / unclassified 0.1 % Other
Background Nutrilipid Unknown 0.1 % Other

Indications